TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04950478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: 5 minutes before the procedure, they were recorded on 'Child and Parent Information Form', State-Trait Anxiety Inventory for Children and FPS-R. Their heart rate and oxygen saturation values were read and recorded. Children wore the virtual reality headset and game was started one minute before the venipuncture. As soon as the injector inserted, the researcher turned on a stopwatch and read and recorded heart rate and oxygen saturation values. When the injector was removed, the researcher stopped the stopwatch and recorded the duration of the procedure.When the injector was removed, the stopwatch was stopped and heart rate and oxygen saturation were recorded. The children took off the virtual reality headset and were asked to evaluate their pain level through FPS-R and their responses were recorded.
Study: NCT03743935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced cardiac MRI
Description: Gadolinium-enhanced cardiac MRI during the 1st days post-STEMI with specific sequences including extra-cellular volume measurement
Study: NCT00329524

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
Study: NCT04504409

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Training
Study: NCT00795119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy (NIRS)
Description: NIRS of the head is undertaken at the time of CT or MRI examination
Study: NCT03108313

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoride toothpaste
Description: chemical toothpaste used to decrease salivary streptococcus bacterial count
Study: NCT01628185

Intervention type: PROCEDURE
Intervention: Repositioning
Description: pain assessment at baseline then following routine care repositioning in bed
Study: NCT03593616

Intervention type: PROCEDURE
Intervention: Phacoemulsification
Description: insertion of intra-ocular lens after emulsification of catractous lens
Study: NCT02681354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorescue training
Study: NCT04064216

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis

Intervention type: PROCEDURE
Intervention: Laparoscopic surgery
Description: Patients that will undergo robot assisted laparoscopic surgery and conventional laparoscopic surgery for benign gynecologic disorders will answer 4 questionnaires to assess patient satisfaction, quality of life and cosmesis
Study: NCT04570553

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical staging
Description: Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
Study: NCT03698591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation task
Description: Experimenters will employ a continuous theta-burst stimulation (cTBS) sequence using a figure-8 coil positioned tangentially to the scalp over the target coordinates. Experimenters have defined the target coordinates for stimulation (Montreal Neuroscience Institute coordinates -53, -53, 23) based on peak objective distancing activation in the left temporal parietal junction (TPJ) in previous fMRI studies using the same task.
Study: NCT04570553

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical staging
Description: Patients will undergo standard surgical staging for endometrial cancer utilizing either a V-care uterine manipulator or sponge stick
Study: NCT03698591

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial magnetic stimulation task
Description: A sham version of the TMS intervention where subjects will receive a small electrical stimulation on the scalp via two small electrodes in conjunction with a TMS coil activation. The TMS coil will be reoriented to stimulate into the air away from the scalp, simulating traditional TMS, without inducing any current to the subject.
Study: NCT02714322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MYL-1401A (Adalimumab)
Description: MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira® (Adalimumab)
Description: Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
Study: NCT02369172

Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion

Intervention type: DRUG
Group type: OTHER
Intervention: ASP2151
Study: NCT01011309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F2 + MPL-SE
Description: 10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium stibogluconate
Description: 20 mg/kg/day IV daily for 20 days
Study: NCT01750749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous BMDC implantation at the venous ulcer
Description: An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
Study: NCT03858816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mixture probiotics
Description: The mixture probiotics capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contains the same excipient ingredients but without the live bacteria.
Study: NCT03807375

Intervention type: OTHER
Group type: OTHER
Intervention: CPAP preoxygenation
Description: During preoxygenation, the ventilator device will be placed in spontaneous mode and set as CPAP: 5 cmH2O.
Study: NCT03175666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT00495898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CYPHER sirolimus-eluting stent
Description: drug-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated Bx VELOCITY balloon-expandable stent
Description: bare metal stent
Study: NCT03175666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: omega-3-acid ethyl esters)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: (SBRT)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: recombinant human super agonist interleukin-15 (IL-15) complex

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: adenovirus serotype-5 \[Ad5\] \[E1-, E2b-\]-CEA (carcinoembryonic antigen)
Study: NCT00610480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st visit Optive, then 2nd visit Systane
Description: First visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.
Study: NCT03175666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-mucin 1 (MUC1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: RAS yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: CEA yeast vaccine
Study: NCT00610480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1st visit Systane, then 2nd visit Optive
Description: First visit: Instillation of Systane followed by evaporometry assessment after 30 minutes.~Second visit: Instillation of Optive followed by evaporometry assessment after 30 minutes.
Study: NCT04326426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Neurokinin-1 antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT03801044

Intervention type: DIAGNOSTIC_TEST
Intervention: NT-BNP, VEGF
Description: VEGF-C levels were measured in the serum samples. R\&D Systems kit (Minneapolis, MN) (Catalog Number DVEC00) was used for the assays according to the user instructions. NT-proBNP was measured on the Elecsys 2010 analyzer (Elecsys proBNP Immunoassay; Roche Diagnostics).

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Transthoracic echocardiography was performed by the same cardiologist blinded to all other parameters. It was done while abdomen was empty. LV end diastolic diameter (mm), interventricular septum thickness (mm), posterior wall thickness (mm), ejection fraction (%), left ventricle end diastolic volume (ml), left atrial volume (ml), left ventricle mass index (LVMI) (g/m2), left ventricle filling velocity(cm/sec), E/E' ratio, pulmonary artery systolic pressure (mm Hg) were the parameters taken by echocardiography

Intervention type: RADIATION
Intervention: Chest Radiography
Description: All radiographies were taken when the patient was standing erect position during deep inhalation. They were reported by an expert radiologist blinded to clinical data. Films taken at supine position or during exhalation were excluded. Chest radiographies were classified into 3 stages to reflect degree of hypervolemia. Stage 1 was redistribution defined as increased artery-to-bronchus ratio in the upper and middle lobes. Stage 2 was interstitial edema evident by Kerley B lines and peribronchial cuffing. Stage 3 was alveolar edema phase perihilar consolidation and air bronchograms, pleural fluid, increased width of the vascular pedicle, enlarged cardiac silhouette.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: It was performed by 28 area method which contains ultrasound examination from second to fifth intercostals spaces at parasternal region, midclavicular line, anterior and mid axillary lines. Lung ultrasound had been done by same radiologist who was an expertise in ultrasonography blinded to all other parameters. It was performed by 1,6 megaHertz convex probe when patient lying at the supine position.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedence Analysis
Description: The Body Composition Monitor (BCM) (type 0BJA1394, Fresenius Medical Care AG \& Co. KGaA, D-61343 Bad Homburg) was used for assessment of hydration status in patients. Peritoneal cavities were free of intraperitoneal fluid during measurement. Patients were accepted as normovolemic if their result were between -1.1lt and 1.1 lt.
Study: NCT02814994

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tidal volume guided by respiratory system compliance
Description: ventilated with tidal volume guided by respiratory system compliance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low tidal volume
Description: ventilation ventilated with low tidal volume
Study: NCT03645434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8871
Description: Randomized patients will receive 14 repeated daily doses of AZD8871 600 µg inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anoro® Ellipta®
Description: Randomized patients will receive 14 repeated daily doses of Anoro® Ellipta® (55 µg/22 µg) inhalation powder via DPI.
Study: NCT01798108

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (BAY88-8223)
Description: - Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
Study: NCT02759718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chromogranin A
Description: The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
Study: NCT03180918

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: testicular tissue biopsy
Description: testicular tissue biopsy during general anesthesia
Study: NCT02064582

Intervention type: DRUG
Group type: OTHER
Intervention: Enzalutamide
Description: 160mg by mouth each day

Intervention type: DRUG
Group type: OTHER
Intervention: Leuprolide acetate
Description: 22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation
Description: External beam radiation will be delivered as per standard radiation therapy protocol
Study: NCT01590888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBT2
Description: 250mg capsules administered orally once per day for 26 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBT2
Description: 100mg capsules administered orally once per day for 26 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching capsules administered orally once per day for 26 weeks
Study: NCT02334540

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: purses
Description: food intake
Study: NCT03175666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Brachyury yeast vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\], Suspension for Intravenous \[IV\] Infusion (haNK™ for Infusion)
Study: NCT02334540

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: a calorie/protein matched smoothie
Study: NCT00879229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
Study: NCT00684060

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adult stem cells
Description: One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time infusion of 30 ml of HSA (5%)
Study: NCT02331277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655064
Description: subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00696917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection 3 different vaccine lots

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection 3 different vaccine lots

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine 208129
Description: 2-dose intramuscular injection 3 different vaccine lots

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT00879229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ambrisentan
Description: Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
Study: NCT02052492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Study: NCT00879229

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ambrisentan administered orally once daily.
Study: NCT02085889

Intervention type: OTHER
Intervention: no intervention: observational study
Description: observational
Study: NCT02052492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)
Study: NCT02707822

Intervention type: OTHER
Intervention: Clinical and genetic factors
Study: NCT02310204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multidisciplinary education program
Description: both individual and group education sessions over a 6-month period in addition to standard psoriasis care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard psoriasis care alone
Study: NCT01574183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: up to 40 mg capsule daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 40 mg capsule daily
Study: NCT04603027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP1815
Description: EDP1815 is an orally administered, pharmaceutical preparation of a single strain of bacteria

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule